[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 31, 1966

Pharmacology, Toxicity, and Therapeutic Usefulness of Amphotericin B

Author Affiliations

From the National Institute of Allergy and Infectious Diseases, Laboratory of Clinical Investigations, Clinical Immunology Section, Bethesda, Md.

JAMA. 1966;195(5):371-375. doi:10.1001/jama.1966.03100050079024
Abstract

The polyene antibiotic, amphotericin B, has been used clinically for nearly ten years, and during this time, it has played a paramount role in the treatment of systemic fungal diseases. Recently reported studies not only have confirmed the early favorable reports but have served to define more clearly the degree of effectiveness of the drug in treatment of specific fungal infections. In addition, certain aspects of the pharmacological and toxic properties of the drug have been explained.

Drug Preparations  Amphotericin B is available in two types of preparations, one which forms a microcrystalline suspension and the other which forms a colloidal suspension in water.

Microcrystalline Preparation.—  This material is marketed in two forms. The first is for topical application and includes 3% amphotericin B in appropriate vehicles to form a lotion, cream, or ointment. It has been used for topical application in superficial Candida infections.1 The second, or oral

First Page Preview View Large
First page PDF preview
First page PDF preview
×